Mark T Osterman

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. doi request reprint Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
    Mark T Osterman
    Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Electronic address
    Clin Gastroenterol Hepatol 13:1293-1301.e5; quiz e70, e72. 2015
  2. doi request reprint Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease
    Mark T Osterman
    University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania Electronic address
    Gastroenterology 146:941-9. 2014
  3. doi request reprint Mucosal healing in inflammatory bowel disease
    Mark T Osterman
    Pennsylvania Presbyterian Medical Center, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Gastroenterol 47:212-21. 2013
  4. pmc No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease
    Mark T Osterman
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 9:875-80. 2011
  5. pmc Comparative effectiveness of infliximab and adalimumab for Crohn's disease
    Mark T Osterman
    Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Clin Gastroenterol Hepatol 12:811-817.e3. 2014
  6. doi request reprint Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
    Frank I Scott
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia2Division of Gastroenterology, University of Pennsylvania, Philadelphia
    JAMA Dermatol 152:164-72. 2016
  7. doi request reprint Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection
    Maria Paula Henao
    Departments of Medicine, and Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Departments of Medicine and Public Health Sciences, Pennsylvania State College of Medicine, Hershey, Pennsylvania
    Inflamm Bowel Dis 21:2262-71. 2015
  8. pmc Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model
    Frank I Scott
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Division of Gastroenterology and Nutrition, Department of Paediatrics, Anna Meyer Children s Hospital, University of Florence, Florence, Italy
    Inflamm Bowel Dis 19:2625-33. 2013
  9. doi request reprint A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
    David S Kotlyar
    Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Clin Gastroenterol Hepatol 9:36-41.e1. 2011
  10. pmc Passive smoking and inflammatory bowel disease: a meta-analysis
    Deborah T Jones
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6021, USA
    Am J Gastroenterol 103:2382-93. 2008

Collaborators

Detail Information

Publications19

  1. doi request reprint Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
    Mark T Osterman
    Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Electronic address
    Clin Gastroenterol Hepatol 13:1293-1301.e5; quiz e70, e72. 2015
    ..This study assessed the effectiveness and safety of immunomodulators with anti-TNF therapy in CD...
  2. doi request reprint Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease
    Mark T Osterman
    University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania Electronic address
    Gastroenterology 146:941-9. 2014
    ..We also compared the risk of malignancy associated with combination adalimumab and immunomodulator therapy with that of adalimumab monotherapy...
  3. doi request reprint Mucosal healing in inflammatory bowel disease
    Mark T Osterman
    Pennsylvania Presbyterian Medical Center, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Gastroenterol 47:212-21. 2013
    ..However, the use of mucosal healing as a therapeutic endpoint in inflammatory bowel disease is in its early stages, as a number of issues limit its application to routine clinical practice...
  4. pmc No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease
    Mark T Osterman
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 9:875-80. 2011
    ..We aimed to determine the risk of first-time acute MI in patients with ulcerative colitis (UC) or Crohn's disease (CD) compared with patients from general practice...
  5. pmc Comparative effectiveness of infliximab and adalimumab for Crohn's disease
    Mark T Osterman
    Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Clin Gastroenterol Hepatol 12:811-817.e3. 2014
    ..This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti-tumor necrosis factor agents, in patients with CD...
  6. doi request reprint Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
    Frank I Scott
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia2Division of Gastroenterology, University of Pennsylvania, Philadelphia
    JAMA Dermatol 152:164-72. 2016
    ..Drug-induced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors. For patients with a history of NMSC, data are limited on the effect of these drugs on the risk of additional NMSCs...
  7. doi request reprint Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection
    Maria Paula Henao
    Departments of Medicine, and Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Departments of Medicine and Public Health Sciences, Pennsylvania State College of Medicine, Hershey, Pennsylvania
    Inflamm Bowel Dis 21:2262-71. 2015
    ..The Crohn's Disease Activity Index (CDAI) and Mayo score for ulcerative colitis (UC) require symptom recall and/or use of a symptom diary. We examined patients' abilities to recall their symptoms and the day-to-day variability of symptoms...
  8. pmc Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model
    Frank I Scott
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Division of Gastroenterology and Nutrition, Department of Paediatrics, Anna Meyer Children s Hospital, University of Florence, Florence, Italy
    Inflamm Bowel Dis 19:2625-33. 2013
    ..In this study, we performed a decision analysis assessing the impact of JC virus (JCV) antibody testing and natalizumab utilization for loss of response to infliximab...
  9. doi request reprint A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
    David S Kotlyar
    Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Clin Gastroenterol Hepatol 9:36-41.e1. 2011
    ..We investigated the medications, duration of therapy, and ages of patients associated with HSTCL...
  10. pmc Passive smoking and inflammatory bowel disease: a meta-analysis
    Deborah T Jones
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6021, USA
    Am J Gastroenterol 103:2382-93. 2008
    ..This meta-analysis examined the relationship between prenatal smoke exposure and childhood passive smoke exposure and the development of IBD...
  11. ncbi request reprint Infliximab in fistulizing Crohn's disease
    Mark T Osterman
    Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
    Gastroenterol Clin North Am 35:795-820. 2006
    ..Proper fistula management also relies heavily on accurate diagnosis, especially defining the anatomy of the fistula, ascertaining whether abscess formation is present, and determining the location and extent of intestinal inflammation...
  12. pmc Efficacy of methotrexate in ulcerative colitis: failure or promise
    Hans H Herfarth
    Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Inflamm Bowel Dis 16:1421-30. 2010
    ....
  13. doi request reprint Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates
    Mark T Osterman
    Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Methods Find Exp Clin Pharmacol 31:41-6. 2009
    ..This review article summarizes the data on the use of both conventional aminosalicylates and MMX mesalamine in the treatment of ulcerative colitis...
  14. pmc Secular trends in small-bowel obstruction and adhesiolysis in the United States: 1988-2007
    Frank I Scott
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce St, Ravdin 3, Philadelphia, PA 19104, USA
    Am J Surg 204:315-20. 2012
    ..The impact that laparoscopy and other surgical advances have had on rates of SBO and adhesiolysis remains controversial. This study examines trends in discharges from US hospitals for SBO and adhesiolysis from 1988 to 2007...
  15. ncbi request reprint Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis
    Mark T Osterman
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Gastroenterology 130:1047-53. 2006
    ..Previous studies, most with small sample sizes, yielded conflicting conclusions. Our aim was to pool the available data to provide a more precise estimate of the association between 6-TGN levels and IBD activity...
  16. pmc Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis
    Mark T Osterman
    Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Clin Gastroenterol Hepatol 12:1887-93.e3. 2014
    ..We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC...
  17. ncbi request reprint Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease
    Mark T Osterman
    Gary R Lichtenstein, MD Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Treat Options Gastroenterol 10:195-207. 2007
    ..The future of anti-TNF therapy in inflammatory bowel disease is very bright, as exciting new developments continue to be made at a rapid pace...
  18. ncbi request reprint Perianal skin tags in a patient with Crohn disease and a subclinical rectal stricture
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cutis 80:429-31. 2007
    ..Increasing numbers or size of these lesions may herald worsening of more proximal Crohn disease, as in our patient. We review the epidemiology, classification, and management of perianal skin tags in patients with Crohn disease...
  19. ncbi request reprint Risky business? Crohn's disease-related mortality
    Mark T Osterman
    University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Inflamm Bowel Dis 12:246-8. 2006